Vanda Pharmaceuticals Business Summary

Vanda Pharmaceuticals Inc. (VNDA) is a commercial-stage biopharmaceutical company that generates revenue primarily through the direct sale of proprietary therapies targeting central nervous system (CNS) disorders. Its core revenue streams are derived from three established products: Fanapt (iloperidone) for schizophrenia and bipolar I disorder, HETLIOZ (tasimelteon) for sleep-wake disorders, and PONVORY (ponesimod) for relapsing forms of multiple sclerosis. As of early 2026, the company has expanded its commercial portfolio following the December 2025 FDA approval of NEREUS (tradipitant) for motion-induced vomiting and the anticipated launch of Bysanti (milsaperidone). Vanda operates as a specialized mid-tier player in the neuropsychiatry and orphan drug markets, competing directly with larger firms such as Supernus Pharmaceuticals, Intra-Cellular Therapies, and Acadia Pharmaceuticals by focusing on niche indications and genomic-driven drug development. The company was founded in 2003 by Dr. Mihael H. Polymeropoulos, who continues to serve as President, CEO, and Chairman of the Board. Dr. Polymeropoulos brings a high-pedigree background in pharmacogenetics, having previously established the global pharmacogenetics department at Novartis and conducted pioneering gene-mapping research at the National Institute of Mental Health (NIMH). The executive leadership team includes Kevin Moran as SVP and Chief Financial Officer, Timothy Williams as SVP and General Counsel, and Joakim Wijkstrom as SVP and Chief Marketing Officer. Vanda was originally backed by prominent institutional investors including Care Capital LLC and Bio*One Capital, the investment arm of the Singapore government. The current Board of Directors features veteran industry leaders such as Lead Independent Director Richard W. Dugan and Dr. Stephen Ray Mitchell, providing a blend of clinical expertise and corporate governance.